Shenzhen Noposion Crop Science Co., Ltd.'s (SZSE:002215) price-to-earnings (or "P/E") ratio of 26.4x might make it look like a buy right now compared to the market in China, where around half of the companies have P/E ratios above 36x and even P/E's above 65x are quite common. However, the P/E might be low for a reason and it requires further investigation to determine if it's justified.
Recent times have been pleasing for Shenzhen Noposion Crop Science as its earnings have risen in spite of the market's earnings going into reverse. One possibility is that the P/E is low because investors think the company's earnings are going to fall away like everyone else's soon. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.
See our latest analysis for Shenzhen Noposion Crop Science
![pe-multiple-vs-industry](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240102/0-6276261cdfd8aaf5fa1bd56f5f47cbfd-0-0a14dba432341ebb288c62d3dbcaab2b.png/big)
Is There Any Growth For Shenzhen Noposion Crop Science?
In order to justify its P/E ratio, Shenzhen Noposion Crop Science would need to produce sluggish growth that's trailing the market.
If we review the last year of earnings growth, the company posted a worthy increase of 9.1%. The latest three year period has also seen a 8.1% overall rise in EPS, aided somewhat by its short-term performance. Therefore, it's fair to say the earnings growth recently has been respectable for the company.
Turning to the outlook, the next year should generate growth of 92% as estimated by the four analysts watching the company. With the market only predicted to deliver 43%, the company is positioned for a stronger earnings result.
With this information, we find it odd that Shenzhen Noposion Crop Science is trading at a P/E lower than the market. It looks like most investors are not convinced at all that the company can achieve future growth expectations.
The Bottom Line On Shenzhen Noposion Crop Science's P/E
While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
Our examination of Shenzhen Noposion Crop Science's analyst forecasts revealed that its superior earnings outlook isn't contributing to its P/E anywhere near as much as we would have predicted. There could be some major unobserved threats to earnings preventing the P/E ratio from matching the positive outlook. It appears many are indeed anticipating earnings instability, because these conditions should normally provide a boost to the share price.
Having said that, be aware Shenzhen Noposion Crop Science is showing 3 warning signs in our investment analysis, and 1 of those doesn't sit too well with us.
You might be able to find a better investment than Shenzhen Noposion Crop Science. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.